# Brenig Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brenig-therapeutics

- Industry: Biotechnology
- Headquarters: Dover, US
- Total disclosed funding: $30M
- Latest round: Series A (Jul 16, 2024)
- Investors on record: 4

## About

Based in Delaware, US, and founded in 2021 and led by Chairman Iain Dukes, Brenig Therapeutics Inc. operates as a provider of neurodegenerative disorder therapy for the healthcare industry. In July 2024, Brenig Therapeutics Inc. raised USD 30 million in Series A funding led by New Enterprise Associates, with participation from OrbiMed Advisors, Torrey Pines Investment, and BioGeneration Ventures. As of 2024, the firm operates in stealth mode.  

Brenig Therapeutics Inc. focuses on neurology-based drug development by leveraging artificial intelligence and machine learning platforms. The company specializes in small-molecule therapy development, such as BT-267, which is a small-molecule LRKK2 inhibitor for brain exposure and minimal peripheral exposure.

The company plans to use the funding from July 2024 to support advancing leading pre-clinical development candidate BT-267, a best-in-class leucine-rich repeat kinase 2 (LRRK2) inhibitor, into human clinical trials for the treatment of idiopathic and LRRK2-mutuated Parkinson's disease.

## Funding rounds

- Series A, Jul 16, 2024, $30M — New Enterprise Associates, OrbiMed Advisors, BioGeneration Ventures, Torrey Pines Investment

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Series A
- Torrey Pines Investment (https://capitalatlas.ai/funds/torrey-pines-investment) — Series A